Alteration of the CDKN2A gene in pancreatic cancers: Is it a late event in the progression of pancreatic cancer?

International Journal of Oncology

Volumn 13, Issue 4, 1998, Pages 669-676

  Sugimoto, Yoshihisa ^a   Morita, Ryoji ^a   Hikiji, Kazumasa ^a   Imura, George ^b   Ogata, Yoshiro ^b   Yasuda, Daisuke ^c   Kono, Akira ^d   Iguchi, Haruo ^d  

^a SRL INC   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

CDKN2A; Pancreatic cancer; Progression

Indexed keywords

ARTICLE; CARCINOGENESIS; GENE DELETION; HUMAN; HUMAN TISSUE; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031690421     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.4.669     Document Type: Article

References (27)

1. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/Cdk4. Nature 366: 704-707, 1993.
2. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE and Skolnick MH: A cell-cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
3. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
4. Caldas C, Hahn SA, da Costa LT, Reddston MS, Schutte M, Seymour AB, Weinstein C, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32, 1994.
5. INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049, 1994.
6. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2A (p16/MTS1) gene deletion or CDK 4 amplification occurs in the majority of glioblastoma. Cancer Res 54: 6321-6324, 1994.
7. Yeudall WA, Crawford RY, Ensley JF and Robbins KC: MTS1/CDK4T I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 15: 2683-2686, 1994.
8. Caims P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE and Sidransky D: Rates of p16 (MTS-1) mutations in primary tumors with 9p loss. Science 265: 415-416, 1994.
9. Spruck CH, Gonzales-Zulueta M, Shibata A, Simoneua AR, Lin M-F, Gonzales F, Tsai YC and Jones PA: p16 gene in uncultured tumors. Nature 370: 183-184, 1994.
10. Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunago S, Nobori T, Carson DA, Ridge JA and Goodrow TL: Higher frequency of alterations in the p16/CDKN2A gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54: 5050-5053, 1994.
11. Ink4) in human breast carcinomas. Cancer Res 54: 5262-5264, 1994.
12. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, Nobori T, Olopade OI, Buckler AJ and Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54: 5547-5551, 1994.
13. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T and Terada M: Mutation frequency of the p16/CDKN2A gene in primary cancers in the upper digestive tract Cancer Res 55: 3421-3423, 1995.
14. Capella G, Villanueva A, Erill N and Lluis F: Molecular epidemiology of protooncogene and tumor-suppressor gene mutations. In: Pancreatic Cancer: Molecular and Clinical Advances. Neoptolemos JP and Lamoine NR (eds). Blackwell Sience, Oxford, pp 169-180, 1996.
15. Hahn SA, Seymour AB, Shamsul Hoque ATM, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE: Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55: 4670-4675, 1995.
16. Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozemblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q 21.1. Science 271: 350-353, 1996.
17. Japanese Pancreatic Society: In: General Rules for the Study of Pancreatic Cancer. Kanehara Co., Tokyo, 1993.
18. Morikawa K, Walker SM, Jessup M and Fidler IJ: In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48: 1943-1948, 1988.
19. Asakawa J, Satoh C, Yamasaki Y and Chen S-H: Accurate and rapid detection of heterozygous carriers of a deletion by combined polymerase chain reaction and high-performance liquid chromatography. Proc Natl Acad Sci USA 89: 9126-9130, 1992.
20. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, van Tornout JM and Jones PA: Methylation of the 5'CpG island of the p16/CDKN2A tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535, 1995.
21. Hattori M, Shibata A, Yoshioka K and Sasaki Y: Orphan peak analysis: a novel method for detection of point mutations using an automated fluorescence DNA sequencer. Genomics 15: 415-417, 1993.
22. Huang L, Goodrow TL, Zhang S-Y, Klein-Szanto AJP, Chang H and Ruggeri BA: Deletion and mutation analyses of the p16/ MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 56: 1137-1141, 1996.
23. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ and Kern SE: Tumor-suppressive pathyways in pancreatic carcinoma. Cancer Res 57: 1731-1734, 1997.
24. Schutte M, Hruban RH, Gcradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE and Herman JG: Abrogation of the RB/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126-3130, 1997.
25. INK4A as a human tumor suppressor. Biochem Biophys Acta 1242: 165-169, 1996.
26. Reed JA, Loganzo Fjr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW and Albino AP: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppresor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55: 2713-2718, 1995.
27. Muscarella P, Melvin WS, Fisher WE, Foor J, Ellison EC, Herman JG, Schirmer WJ, Hitchcock CL, De Young BR and Weghorst CM: Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS 1 tumor suppressor gene inactivation. Cancer Res 58: 237-240, 1998.